Related Experiment Videos
[Dose intensity chemotherapy in lung cancer]
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|October 1, 1990
Summary
Dose intensity chemotherapy, delivering more medication over time, shows promise for improving outcomes in small-cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Intensive regimens like CODE and MVP with growth factors yielded positive responses and survival benefits.
Area of Science:
- Oncology
- Pharmacology
- Cancer Research
Context:
- Dose intensity (DI) chemotherapy, defined as drug amount per unit time (mg/m²/wk), is increasingly recognized as crucial for enhancing chemotherapeutic efficacy.
- Previous research and animal models suggest DI's impact across various malignancies.
Purpose:
- To evaluate the impact of dose intensity chemotherapy on small-cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
- To assess the efficacy of intensive chemotherapy regimens and explore strategies to improve treatment delivery in lung cancer patients.
Summary:
- For SCLC patients, a weekly intensive chemotherapy regimen (cisplatin, oncovin, doxorubicin, and etoposide - CODE) resulted in an 88% response rate (29% complete response) and a median survival of 45 weeks.
- For NSCLC patients, a shortened interval (3 weeks) MVP (mitomycin, vindesine, and cisplatin) regimen supported by recombinant human granulocyte-colony stimulating factor (rhG-CSF) allowed 32/40 patients to complete planned cycles, indicating improved treatment feasibility.
Impact:
- These findings suggest that enhanced dose intensity chemotherapy can significantly improve treatment outcomes for patients with both SCLC and NSCLC.
- The study highlights the potential of intensive chemotherapy schedules and supportive care (rhG-CSF) in optimizing lung cancer treatment strategies.